Quarterly Report I / 2026

1 January - 31 March

Eckert & Ziegler

Confnibufin to saris lives

(*) Previous year's figures have been restated to reflect the share split in August 2025

The official version of the Eckert & Ziegler quarterly report is in German. The English translation is provided as a convenience to our shareholders. While we strive to provide an accurate and readable version of our quarterly report in English, the technical nature of a quarterly report often yields awkward phrases and sentences. We understand this can cause confusion. So, please always refer to the German quarterly report for the authoritative version.

MILESTONES

ECKERT &

ZIEGLER PARTICIPATES IN THE J.P.

MORGAN HEALTHCARE CONFERENCE

Eckert & Ziegler presents its business strategy at the J. P. Morgan Healthcare Conference in San Francisco, one of the world's most

important pharmaceutical conferences for institutional investors and compa-

nies in the healthcare sector.

Under the agreement, Eckert & Ziegler will support Molecular Partners with a comprehensive range of services covering development activities for Radio-DARPins with Actinium-225 and Lutetium-177 payloads which show potential in the

treatment of various cancers.

DIVIDEND PROPOSAL

The Executive Board and Supervisory Board resolved to propose to the Annual General Meeting the payment of a dividend of €0.22 (previous year, split adjusted: €0.17) per dividend-bearing share. The dividend pay-

ment is subject to the resolution of the Annual General Meeting.

Eckert & Ziegler and the Nuclear Physics Institute of the Czech Academy of Sciences (UJF) have successfully transitioned their joint Actinium-225 initiative into larger scale manufacturing using the facilities in Ăež

and Braunschweig.

1. GROUP INTERIM MANAGEMENT REPORT
   1. EARNINGS PERFORMANCE

      Revenue

      Overall, the Group reported revenue growth of ; as of the end of March , revenue stood at . million, an increase of . million over the previous year's figure of . million.

      The following trends are evident in the individual segments:

      External revenue in the Medical segment amounted to . million in the first three months of the year, significantly exceeding the previous year's figure (. million). The pharmaceutical radioisotopes business remains the most important source of revenue. Of particular note are the trends in revenue from generators and in the Contract Manufacturing & Development (CDMO) sector. To facilitate a better comparison with the same quarter of the previous year, two events should be highlighted: the delays caused by the cyberattack in February  and the associated, short-term suspension of deliveries of gallium generators had a negative impact on revenue in the Medical segment. These delays were largely only made up for in the second quarter of . Furthermore, revenue from the licensing business amounted to . million in the first quarter of ; no revenue from the licensing business has been realised in  to date.

      The Isotope Products segment generated external revenue of . million, which was . million or approximately  lower than in the first three months of the previous year. A strong fourth quarter of  was followed by a subdued start to the year, which regained significant momentum in March. Overall, the product mix was somewhat weaker.

      EBIT (earnings before interest and taxes) from continuing operations before special items (adjusted EBIT)

      For the reconciliation from EBIT to adjusted EBIT, please refer to the information in the notes to the interim consolidated financial statements in the section 'Key performance indicators defined by management'.

      The Group's adjusted EBIT fell by around . million to . million compared with the first three months of the previous year, representing a decrease of .

      In the Medical segment, adjusted EBIT stood at . million, which was . million higher than the adjusted EBIT for the same period last year. Gross profit rose by . million to . million, whilst the gross margin improved by around

       percentage point to . This improvement in earnings and margins is primarily attributable to the high-margin sales of generators mentioned above.

      In the Isotope Products segment, adjusted EBIT fell by around . million to . million. This was primarily due to the decline in gross profit by . million to . million. The gross margin fell from  in the previous year to  in the first three months of the year. The main reason for the decline was the effect described above, combined with the shift between product groups.

      The Other segment, comprising the holding company, closed the first three months of the year with an adjusted EBIT of -. million (previous year: - thousand). The change is primarily due to the retrospective adjustment of share-based payments under the LTI bonus programme.

      Earnings (net profit for the period)

      The Group's quarterly profit of . million, or . per share, was approximately . million () higher than the previous year's result.

      Consolidated earnings were positively impacted by currency effects of . million in the first three months of , whereas in the same period of the previous year, they were negatively impacted by currency effects of . million.

      In the Medical segment, net profit stood at . million (previous year: . million). Currency effects of . million had positive impact on the result; in the previous year, currency effects resulted in a loss of . million. Net interest income declined by . million compared with the previous year, to -. million.

      In the Isotope Products segment, net profit fell by around . million compared with the same period last year to . million. Currency effects (. million) had a positive impact on the result of . million compared with the previous year. Losses under IAS  (Hyperinflation) amounted to . million in the reporting period (previous year: . million).

      The Other segment closed the first three months of the year with a net loss of . million (previous year: . million).

   2. ASSETS AND FINANCIAL POSITION

      Balance Sheet

      The balance sheet total at the end of March  increased by . million compared with the  annual financial statements and now stands at  million (previous year:  million).

      On the assets side, the increase is primarily attributable to the rise in property, plant and equipment by . million to

      . million. This is mainly due to investments in land and buildings as well as in production facilities, including the expansion and modernisation of existing facilities and ongoing replacement investments. In addition, the exercise of the convertible bond by Pentixapharm Holding AG led to an increase in financial assets of . million. Trade receivables increased by . million to . million. In addition, income tax receivables rose by . million to . million during the reporting period (as at  December : . million).

      On the liabilities side, the increase is primarily attributable to higher income tax liabilities, which rose by . million to

      . million (previous year: . million), as well as to the increase in equity.

      Equity rose by . million to  million as at  March . This increase is primarily attributable to the profit for the period of . million, as well as to the . million increase in other reserves resulting from positive foreign currency translation differences (including EUR-USD), which were recognised in other comprehensive income. The equity ratio stands at .

      As at  March , . million was reported as long-term loan liabilities and . million as short-term loan liabilities.

      Liquidity

      Operating cash flow, at . million, is below the previous year's level (previous year: . million). This is primarily due to tax payments of . million, which were significantly lower in the comparative period (. million).

      The cash outflow from investing activities (. million) results from investments in intangible assets and property, plant and equipment (. million) as well as the payment of . million for the acquisition of convertible bonds from Pentixapharm Holding AG, which exercised its call option in the first quarter of  to redeem part of the convertible bond. The main focus of investment was on the expansion of the sites in Wilmington, USA (focus: Lu-), São Paulo, Brazil (focus: SPECT), Berlin-Buch in the former 'laundry' (focus: Ga-), and Braunschweig (focus: infrastructure for analytical and microbiological laboratory services). There were no corporate acquisitions or disposals during the reporting period.

      The cash outflow from financing activities (. million) is primarily attributable to the repayment of loan liabilities amounting to . million (previous year: . million) and the repayment of lease liabilities amounting to . million (previous year: . million).

      In total, cash and cash equivalents as at  March  decreased by . million compared with the end of  to

      . million (as at  December : . million).

   3. OUTLOOK

      The forecast for the  financial year published on  March  remains unchanged. The Executive Board continues to anticipate revenue of around  million and adjusted EBIT of around  million.

   4. RISKS AND OPPORTUNITIES

      In the  Annual Report, we described risks that could have a significant adverse impact on our business, assets, financial position and results of operations, as well as our reputation. We also outlined the most significant opportunities and the structure of our risk management system. Among the multitude of risks, the potential impact of international trade and sanctions policy certainly represents one of the current challenges. In particular, geopolitical developments relating to the conflict in the Middle East are leading to increased uncertainty in the economic environment. At the time of reporting, however, this has not resulted in any material impact on the Eckert & Ziegler Group's net assets, financial position and results of operations.

      Additional risks and opportunities of which we are unaware, or which we currently consider immaterial, could also affect our business activities. At present, no risks have been identified which, individually or in combination with other risks, could jeopardise the Group's continued existence.

   5. ADDITIONAL INFORMATION

      Employees

      As at  March , the Eckert & Ziegler Group employed , staff worldwide. Compared with the previous year ( December : ,), the number of employees has thus fallen slightly.

2. INTERIM CONSOLIDATED FINANCIAL STATEMENTS

   B.1 CONSOLIDATED INCOME STATEMENT
   CONSOLIDATED INCOME STATEMENT
   		3-Month Report	3-Month Report
   € thousand		1-3/2025	1-3/2026
   Revenues		68,194	72,946
   Cost of sales		-34,112	-36,931
   Gross profit on sales		34,082	36,014
   Selling expenses		-6,701	-6,804
   General and administrative expenses		-10,826	-12,049
   Impairment losses/reversals under IFRS 9		22	-8
   Other operating income		431	281
   Other operating expenses		-1,240	-1,469
   Operating result		15,768	15,965
   Result from investments valued at equity		218	67
   Result from valuation of financial instruments		50	44
   Currency gains		436	653
   Curency losses		-1,225	-342
   Loss under IAS 29 (hyperinflation)		-297	-283
   Earnings before interest and taxes (EBIT)		14,950	16,105
   Interest received		715	574
   Interest paid		-725	-1,046
   Earnings before tax (EBT)		14,939	15,633
   Income tax		-5,109	-5,197
   Consolidated profit		9,831	10,436
   Profit (+)/loss (-) attributable to minority interests		-139	-63
   Net profit attributable to the shareholders of Eckert & Ziegler SE		9,691	10,372
   Earnings per share
   Basic (€ per share)		0.16	0.17
   Diluted (€ per share)		0.16	0.17
   Average number of shares in circulation (basic - in thousands)(*)		62,514	62,576
   Average number of shares in circulation (diluted - in thousands)(*)		62,532	62,798
   (*) Previous year's figures adjusted to reflect the share split in August 2025

   B.2 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

   CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME		3-Month report	3-Month report
   € thousand		1-3/2025	1-3/2026
   Consolidated net income		9,831	10,436
   thereof attributable to the shareholders of Eckert & Ziegler SE		9,691	10,372
   thereof profit (+)/loss (-) attributable to non-controlling interests		139	63
   Items that may be reclassified to the income statement in the future
   under certain circumstances
   Exchange rate differences from the translation of foreign business operations during the financial year -2,492			5,371
   Exchange differences arising from the translation foreign operations -2,492			5,371
   Items that will no longer be recognised in the profit and loss account
   Other comprehensive income after tax -2,492			5,371
   Consolidated total comprehensive income 7,339			15,807
   Consolidated comprehensive income attributable to:
   the shareholders of Eckert & Ziegler SE 7,200			15,762
   Non-controlling interests 139			45

   B.3 CONSOLIDATED BALANCE SHEET
   CONSOLIDATED BALANCE SHEET € thousand		31/12/2025	31/03/2026
   ASSETS
   Non-current assets
   Goodwill		34,580	35,418
   Other intangible assets		11,104	11,750
   Property, plant and equipment		106,324	111,082
   Right-of-use assets (IFRS 16)		29,207	29,071
   Investments in associates or joint ventures		15,890	16,533
   Deferred tax assets		11,582	12,938
   Other non-current assets		1,285	4,292
   Total non-current assets		209,972	221,085
   Current assets
   Cash and cash equivalents		128,688	123,780
   Securities		72	91
   Trade accounts receivables		44,958	51,644
   Contract assets		12,450	12,531
   Inventories		45,972	47,774
   Income tax receivables		7,393	11,304
   Other current assets		8,420	8,322
   Total current assets		247,954	255,445
   Total assets		457,926	476,529
   EQUITY AND LIABILITIES
   Shareholder´s equity
   Subscribed capital		63,516	63,516
   Capital reserves		28,381	29,222
   Retained earnings		166,334	176,706
   Other reserves		-2,875	2,516
   Own shares		-3,588	-3,578
   Portion of equity attributable to the shareholders of Eckert & Ziegler SE		251,767	268,381
   Minority interests		1,654	1,264
   Total shareholder´s equity		253,422	269,645
   Non-current liabilities
   Long-term debt		7,139	5,624
   Non-current lease liabilities (IFRS 16)		28,088	27,957
   Deferred grants and other deferred items (non-current)		1,814	1,736
   Deferred tax liabilities		3,940	5,227
   Retirement benefit obligations		9,238	9,228
   Other non-current provisions		80,627	80,203
   Other non-current liabilities		1,879	2,048
   Total non-current liabilities		132,725	132,024
   Current liabilities
   Short-term dept		6,313	6,326
   Current portion of lease obligations (IFRS 16)		3,265	3,358
   Trade accounts payables		9,375	9,368
   Advance payments received		6,648	5,538
   Deferred income from grants and other deferred income (current)		248	246
   Income tax liabilities		6,748	11,896
   Other current provisions		8,841	9,051
   Other current liabilities		28,334	27,497
   Contractual liabilities		2,008	1,579
   Total current liabilities		71,779	74,860
   Total equity and liabilities		457,926	476,529

   B.4 CONSOLIDATED CASH FLOW STATEMENT
   CONSOLIDATED CASH FLOW STATEMENT
   		3-Month report 01/01/2025-		3-Month report 01/01/2026-
   € thousand		31/03/2025		31/03/2026
   Cash flow from operating activities
   Consolidated profit from continuing operations		9,831		10,436
   Adjustments for:
   Depreciation and value impairments		3,214		3,991
   Net interest income [interest expense (+)/- income (-)]		10		534
   Income tax expense		5,109		5,197
   Income tax payments		-478		-4,236
   Non-cash income from the release of deferred grants		-71		-78
   Gain(-)/loss on the disposal of non-current assets		0		-3
   At-equity results and other		-218		-132
   Change in non-current provisions, other non-current liabilities		-355		-264
   Change in other non-current assets and receivables		5,587		85
   Other non-cash items		-366		5
   Changes in current assets and liabilities:
   Receivables		-12,149		-6,685
   Inventories		-4,317		-1,802
   Change in other current assets		1,444		-5,269
   Change in current liabilities and provisions		-289		3,397
   Cash flow from operating activities		6,953		5,175
   Cash flow from investing activities
   Payments for intangible assets and property, plant and equipment		-4,859		-5,603
   Proceeds from participations		0		41
   Payments for the acquisition of convertible bonds (Pentixapharm)		0		-3,000
   Cash outflow from investing activities		-4,859		-8,562
   Cash flow from financing activities
   Proceeds for loan repayments		-1,591		-1,582
   Disbursements for the payment of lease liabilities		-386		-1,167
   Interest received		715		574
   Interest paid		-184		-113
   Cash outflow from financing activities		-1,446		-2,287
   Changes in cash and cash equivalents due to exchange rate fluctuations		-788		766
   Decrease/increase in cash and cash equivalents		-141		-4,909
   Cash and cash equivalents at the beginning of the period		118,221		128,688
   Cash and cash equivalents at the end of the period		118,079		123,780

   Eckert & Ziegler Quarterly Report I - 2026

   1. CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY

      CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY

      11

      Cumulative other equity itmes

      					Unrealised net income/	Foreign		Equity attributable to
      Amounts in € thousand,		Nominal	Capital	Retained	expense from actuarial	currency exchange	Treasury	shareholders of Eckert &	Non- controlling	Consolidated
      excluding subscribed capitals	Number	value	reserves	reserves	gains/losses	differences	shares	Ziegler SE	interests	equity
      Balance as at 1 January 2025	21,171,932	21,172	68,897	127,998	-1,491	9,956	-3,081	223,451	1,763	225,214
      Total income and expenses recognised directly in equity	0	0	0	0	0	-2,491	0	-2,491	0	-2,491
      Consolidated net income	0	0	0	9,691	0	0	0	9,691	139	9,830
      Consolidated comprehensive income	0	0	0	9,691	0	-2,491	0	7,200	139	7,339
      Share-based remuneration	0	0	163	0	0	0	28	191	0	191
      As at 31 March 2025	21,171,932	21,172	69,060	137,689	-1,491	7,465	-3,053	230,841	1,902	232,744

      CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY

      Cumulative other equity itmes

      					Unrealised net income/	Foreign		Equity attributable to
      Amounts in € thousands,		Nominal	Capital	Retained	expense from actuarial	currency exchange	Treasury	shareholders of Eckert &	Non- controlling	Consolidated
      excluding subscribed capital	Number	value	reserves	reserves	gains/losses	differences	shares	Ziegler SE	interests	equity
      Balance as at 1 January 2026	63,515,796	63,516	28,381	166,334	-812	-2,063	-3,588	251,767	1,654	253,422
      Total income and expenses recognised directly in equity	0	0	0	0	0	5,389	0	5,389	-18	5,371
      Consolidated net income	0	0	0	10,374	0	0	0	10,374	63	10,437
      Consolidated comprehensive income	0	0	0	10,374	0	5,389	0	15,763	45	15,808
      Dividend payment/resolution	0	0	0	0	0	0	0	0	-436	-436
      Share-based remuneration	0	0	841	0	0	0	10	851	0	851
      As at 31 March 2026	63,515,796	63,516	29,222	176,708	-812	3,326	-3,578	268,381	1,264	269,645

   2. NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

   General Information

   These interim consolidated financial statements as at  March  comprise the financial statements of Eckert & Ziegler SE and its subsidiaries.

   Accounting policies

   The condensed interim consolidated financial statements of Eckert & Ziegler SE as at  March  have been prepared in accordance with IAS , the International Financial Reporting Standards (IFRS) applicable to interim reporting. All standards of the International Accounting Standards Board (IASB), London, applicable in the EU as at the reporting date, as well as the valid interpretations of the International Financial Reporting Interpretations Committee (IFRIC) and the Standing Interpretations Committee (SIC), have been taken into account. The interim report does not include all the notes to the financial statements that are usually included in financial statements for a full financial year and is therefore condensed. Accordingly, the interim financial statements should be read in conjunction with the consolidated financial statements of Eckert & Ziegler SE as at  December . The accounting policies set out in the notes to the  consolidated financial statements have been applied unchanged, except in respect of the first-time application of amended standards, which, however, had no impact.

   The new standard IFRS  (Presentation and Disclosure in Financial Statements) has been published by the IASB and is to be applied by the Company from the mandatory first-time application date. The Company is currently working on the analysis and implementation of the new requirements. The provisions of IFRS  have not yet been applied in these interim financial statements. Based on the current status of the analysis, the first-time application is expected to have a minor impact on the presentation and structure of the financial statements, without any material effects on the financial position, results of operations or cash flows. Furthermore, there are extended disclosure requirements in the notes, in particular regarding key performance indicators defined by management.

   The preparation of the consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amount and presentation of recognised assets and liabilities, income and expenses. Actual figures may differ from these estimates. Key assumptions and estimates are made regarding the useful life of assets, the recoverable amounts of fixed assets, the collectability of receivables, and the recognition and measurement of provisions. Due to rounding, individual figures may not add up exactly to the stated total.

   This interim report contains all the necessary information and adjustments required to present a true and fair view of the financial position, results of operations and cash flows of Eckert & Ziegler SE as at the date of the interim report. The interim results for the current financial year do not necessarily allow conclusions to be drawn regarding the development of future results.

   Scope of consolidated financial statements

   The consolidated financial statements of Eckert & Ziegler SE include all companies in which Eckert & Ziegler SE has the ability, directly or indirectly, to determine financial and business policy (control concept).

   Acquisitions and disposals of companies

   There were no acquisitions or disposals of companies in the first three months of the year.

   Change in assignment

   The scope of consolidation has not changed compared with  December .

   Currency translation

   The financial statements of companies outside the European Monetary Union are translated using the functional currency method. The following exchange rates were used for currency translation:

   1.1498

   24.5140

   0.8683

   6.0065

   1,594.5516

   7.9341

   46.7342

   1.1707

   24.325

   0.8683

   6.1567

   8.1064

   44.230

   Exchange rate Exchange rate Average rate Average rate Country Currency on 31/03/2026 on 31/03/2025 01/01-31/03/2026 01/01-31/03/2025

   USA USD

   CZ CZK

   GB GBP

   BR BRL

   ARG ARS

   CHN CNY

   UY UYU

   1.0815

   24.9620

   0.8354

   6.2507

   1,161.64

   7.8442

   45.552

   1.0524

   25.0804

   0.8356

   6.1610

   7.6554

   45.5519

   Equity and treasury stock

   61,658

   8,623

   2,664

   72,946

   As at  March , Eckert & Ziegler SE held , treasury shares. This corresponded to a . stake in the com-pany's share capital.

   Revenue recognition Revenue for the first six months is broken down as follows:
   € thousand					31/03/2026	31/03/2025
   Revenue from the sale of goods						54,890
   Revenue from the provision of services						10,644
   Revenue from customer-specific manufacturing and project contracts (POC)						2,659
   Total						68,194
   Segment information
   SEGMENT REPORT - Income Statement Isotope Products Medical				Other	Elimination	Total
   € thousand	1-3/2026 1-3/2025	1-3/2026 1-3/2025	1-3/2026 1-3/2025	1-3/2026 1-3/2025	1-3/2026 1-3/2025

   Sales to external customers	31,479	33,810	41,467	34,383	0	0	0	0	72,946	68,194
   Sales to other segments	1,668	1,264	107	0	0	0	-1,776	-1,264		0
   Total segment sales	33,147	35,074	41,574	34,383	0	0	-1,776	-1,264	72,946	68,194
   Result from investments valued at equity	65	230	2	-12	0	0	0	0	67	218
   Segment profit before interest and income tax (EBIT) - before special items	2,893	5,500	13,959	10,690	-887	47	0	0	15,965	16,237
   Segment profit before interest and income tax (EBIT)	2,839	4,793	14,052	10,178	-787	-21	0	0	16,105	14,950
   Interest income/expenses	-259	28	-259	-50	45.91293	12	0	0	-472	-10
   Income taxes	-794	-1,226	-4,575	-3,935	172	52	0	0	-5,197	-5,109
   Profit before minority interests	1,786	3,595	9,218	6,193	-569	43	0	0	10,436	9,831

   SEGMENT REPORT - Balance Sheet

   Isotope Products Medical Other Total

   € thousand 31/03/2026 31/12/2025 31/03/2026 31/12/2025 31/03/2026 31/12/2025 31/03/2026 31/12/2025

   Segment assets	246,074	238,274	203,018	196,397	163,484	163,144	612,576	597,815
   Elimination of shares, investments and inter-segment receivables							-136,046	-139,889
   Consolidated total assets							476,529	457,926
   Segment liabilities	-124,457	-122,339	-79,305	-82,987	-21,562	-21,504	-225,324	-226,830
   Elimination of liabilities between segments							18,439	22,326
   Consolidated liabilities							-206,884	-204,504
   Investments in associates	2,620	2,585	13,913	13,305	0	0	16,533	15,890

   	Isotope Products	Medical	Other	Total
   € thousand	1-3/2026 1-3/2025	1-3/2026 1-3/2025	1-3/2026 1-3/2025	1-3/2026 1-3/2025

   Investments (excluding business acquisitions)	2,282	2,838	3,814	2,009	287	12	6,383	4,859
   Depreciation and amortisation, including RoU under IFRS 16	-1,896	-1,542	-1,811	-1,557	-283	-114	-3,991	-3,214
   Impairment	2	22	-11	0	0	0	-8	22

   Key performance indicator defined by management

   Since , 'EBIT before exceptional items' or 'adjusted EBIT' for short has been used as a key performance indicator alongside revenue. This key performance indicator assesses the operational performance of the core business excluding special items. These include financial and currency results, losses under IAS  (hyperinflation), acquisition costs, divestments, impairments or restructuring costs. In the previous year, "restructuring" referred to expenses related to the cyberattack. The financial result summarises the results from equity-accounted investments as well as effects from the valuation of financial instruments and consolidation differences. When calculating this key figure, EBIT is increased by extraordinary expenses and reduced by extraordinary income. The derivation is shown here:

   SEGMENT REPORT

   Isotope Products Medical Other Total

   € thousand 1-3/2026 1-3/2025 1-3/2026 1-3/2025 1-3/2026 1-3/2025 1-3/2026 1-3/2025

   EBIT (only continuing operations)	2,839	4,793	14,052	10,178	-787	-21	16,105	14,950
   Financial result	-47	-194	49	32	-99	-77	-97	-239
   Foreign exchange result	-183	395	-142	362	-1	3	-325	760
   Loss under IAS 29 (Hyperinflation)	283	297	0	0	0	0	283	297
   Divestments	0	0	0	0	0	0	0	0
   Restructuring	0	209	0	118	0	143	0	469
   EBIT before exceptional items	2,893	5,500	13,959	10,690	-887	47	15,965	16,237

   Material transactions with related parties

   In accordance with IAS , transactions with persons or entities that control Eckert & Ziegler SE or are controlled by it must be disclosed. Transactions between the Company and its subsidiaries, which are related parties, have been eliminated in the course of consolidation and are therefore not disclosed. Details of transactions between the Group and other related parties are set out below.

   In addition to the Management Board and members of the Supervisory Board, the following are considered to be other significant related parties and entities for the current financial year:

   • Eckert Wagniskapital und Frühphasenfinanzierung GmbH, which holds . of the shares in Eckert & Ziegler SE and whose principal shareholder, Dr Andreas Eckert, is Chairman of the Supervisory Board of Eckert & Ziegler SE. The Group regards Dr Eckert as a related party and the 'ultimate controlling party', as he previously held an indirect majority of votes at the Annual General Meetings of Eckert & Ziegler SE.

   • ELSA  Beteiligungen GmbH, which is a wholly-owned subsidiary of Eckert Wagniskapital und Frühphasenfinanzierung GmbH.

     In the first quarter of , the following significant transactions were carried out with related parties, all of which were conducted on arm's length terms:

     ELSA  Beteiligungen GmbH has leased a production and administration building in Berlin-Buch to Eckert & Ziegler SE. During the first three months of the year, Eckert & Ziegler SE recognised an expense of  thousand (previous year:  thousand) for the rent. As at  March , lease liabilities to ELSA  Beteiligungen GmbH amounting to

     , thousand (as at  December : , thousand) are recognised in the balance sheet due to the application of lease accounting in accordance with IFRS .

     Ms Jutta Ludwig, former member of the Executive Board and current member of the Supervisory Board of Eckert & Ziegler SE, has many years of specialised operational experience in the business areas of Eckert & Ziegler Radiopharma GmbH. Since  January , she has been making this expertise available to Eckert & Ziegler Radiopharma GmbH as part of additional consultancy services that go beyond her role on the Supervisory Board, with a particular focus on expanding business activities in China. Up to  March ,  thousand was recognised as an expense (previous year:

      thousand).

     The Eckert & Ziegler Group's balances with related parties regarding receivables and payables as at  March  are as follows:

     0

     7,627

     € thousand 31/03/2026 31/12/2025

     Receivables from related parties (excluding Pentixapharm)

     Liabilities to related parties and companies (excluding Pentixapharm)

     0

     7,606

     The Pentixapharm Group regards Dr Eckert as a related party and the 'ultimate controlling party', as he indirectly holds a majority of the voting rights at the general meetings of Pentixapharm Holding AG via Eckert Wagniskapital und Frühphasenfinanzierung GmbH. Transactions with Pentixapharm Holding AG and its subsidiaries are therefore also included in this report.

     Pentixapharm AG purchased services and goods from Eckert & Ziegler Radiopharma GmbH (,) and from Eckert & Ziegler Eurotope GmbH (,).

     Under a subscription agreement dated  August , a convertible bond in the amount of . million was issued between Eckert & Ziegler SE as subscriber and Pentixapharm Holding AG as issuer. The  bonds will only be delivered to Eckert & Ziegler SE once Pentixapharm Holding AG has called for payment from Eckert & Ziegler SE and payment has been made. In the first quarter of , Pentixapharm Holding AG exercised its right of redemption to claim part of the convertible bond (amounting to , thousand). Eckert & Ziegler SE expects Pentixapharm Holding AG to continue to exercise its call option in the near future. This could give rise to a balance sheet risk for the company.

     The balances between the Eckert & Ziegler Group and the Pentixapharm Group regarding receivables, loan receivables including interest and liabilities as at  March  are as follows:

     € thousand	31/03/2026	31/12/2025
     Trade receivables from the Pentixapharm Group	70	40
     Loan receivables from the convertible bond from the Pentixapharm Group	3,000	0
     Receivables from accrued, uncollected interest on the convertible bond	19	0
     Liabilities to the Pentixapharm Group	0	0

     Disclosure on financial instruments

     The financial assets, measured at fair value, comprise the following items as at  March :

   • The Group has hedged a . million loan with a -year term and variable interest rates based on the -month Euribor using an interest rate cap. Like the loan, this interest rate cap has a nominal amount of . million, a term of  years and a similar repayment structure. The strike rate is a -month Euribor of .. As at  March , the fair value of the derivative asset (valuation hierarchy Level ) arising from the interest rate cap was  thousand (as at  December :  thousand). The fair value of the interest rate cap was determined using a standard interest rate option valuation model, taking market parameters into account.

   • As at the balance sheet date, the consolidated balance sheet shows liabilities to banks amounting to , thousand (as at  December : , thousand). The fair value of these loan liabilities is , thousand. The fair value was determined using market parameters.

     The financial liabilities, measured at fair value, comprise the following items as at  March :

   • The convertible bond issued under the subscription agreement dated  August  between Eckert & Ziegler SE as subscriber and Pentixapharm Holding AG as issuer has an impact on the financial statements of Eckert & Ziegler SE. The () bonds will only be delivered to Eckert & Ziegler SE once Pentixapharm Holding AG has called for payment from Eckert & Ziegler SE and payment has been made. Pentixapharm Holding AG exercised its drawing right in the first quarter of , but may still draw down . million. This constitutes a pending transaction; accordingly, the bond itself is not recognised. However, the subscription agreement already gives rise to rights and obligations for the parties, which are expressed in accounting terms as a derivative. This resulted in a liability of

      thousand as at  March  ( December :  thousand) (measurement hierarchy Level ).

   • Eckert & Ziegler does not hedge any balance sheet transaction risks, but exclusively selected operational USD cash flows from its European export business. The hedging structure, which has been in place since March , is premium-neutral and operates as follows: the hedging protection only takes effect from an exchange rate of . USD/, whilst, in return, Eckert & Ziegler forgoes any exchange rate gains above an average level of . USD/. The currency options, which are concluded over a period of one year, thus offer protection against adverse exchange rate movements, but allow only limited opportunities to participate in positive developments. Put simply, with this measure Eckert & Ziegler is trading security for upside potential: the company is hedging against developments that would be detrimental to it, but at the same time is foregoing some of the opportunities to benefit from a significant appreciation of the US dollar. The fair value measurement of the FX hedging instruments was carried out on the basis of a standard option valuation model using relevant market parameters (valuation hierarchy Level ). As at

    March , this resulted in a liability of  thousand.

   The fair value of cash and cash equivalents, current receivables, trade payables and other current trade payables and receivables is approximately equal to their carrying amount. This is primarily due to the short maturity of such instruments.

   Events after the balance sheet date

   There were no events after the balance sheet date that had a material impact on the Group's net assets, financial position or results of operations.

   This interim report contains statements regarding future developments which may constitute forward-looking statements. These statements - like all business activities in a global environment - are always subject to uncertainty. These statements are based on the beliefs and assumptions of the Management Board of the Eckert & Ziegler Group, which are founded on currently available information. Should factors such as macroeconomic or regional developments, changes in exchange rates and interest rates, changes in material costs, or new disruptions arising from the war in Ukraine or other uncertainties occur, or should the assumptions underlying the statements prove to be incorrect, actual results may differ from those forecast. Eckert & Ziegler SE undertakes no obligation and does not intend to update or correct forward-looking statements and information on an ongoing basis. They are based on the circumstances prevailing on the date of their publication.

   This document contains supplementary financial figures which are, or may be, so-called alternative performance measures. When assessing the financial position, results of operations and cash flows of Eckert & Ziegler, these supplementary financial figures should not be used in isolation or as an alternative to the financial figures presented in the consolidated financial statements and calculated in accordance with relevant accounting standards. Due to rounding, it is possible that individual figures in this document may not add up exactly to the stated total, and that the percentages shown may not accurately reflect the absolute values to which they relate.

3. ADDITIONAL INFORMATION
   1. RESPONSIBILITY STATEMENT BY THE STATUTORY REPRESENTATIVES (BALANCE-SHEET OATH)

To the best of our knowledge, we confirm that, in accordance with the applicable accounting standards for interim reporting, the interim consolidated financial statements give a true and fair view of the Group's assets, financial position and results of operations of the Group, and that the interim management report presents the course of business, including the results of operations and the position of the Group, in such a way as to give a true and fair view, and describes the significant opportunities and risks associated with the Group's expected development for the remainder of the financial year.

Berlin,  May 

Dr Harald Hasselmann Dr Gunnar Mann

Chairman of the Executive Board Member of the Executive Board

FINANCIAL CALENDAR

12 May 2026 Quarterly Report i/2026

19 May 2026 Berenberg European Conference 2026, New York 21-22 May 2026 Cantor European Summit, Hamburg

27 May 2026 Rothschild & Co Redburn Radiopharma Conference 2026, New York 24 June 2026 Annual General Meeting, Berlin

13 August 2026 Quarterly Report ii/2026

21-23 September 2026 Berenberg & Goldman Sachs German Corporate Conference, Munich 30 September 2026 NuWays MidCap Konferenz, Paris

12 November 2026 Quarterly Report iii/2026

23-25 November 2026 German Equity Forum, Frankfurt

Subject to change

IMPRINT

PUBLISHER

Eckert & Ziegler SE

DESIGN

2dKontor, Aabenraa, Denmark

PHOTO

Jana Plavec

CONTACT

Eckert & Ziegler SE

Robert-Rössle-Straße 10

13125 Berlin, Germany https://www.ezag.de

Karolin Riehle Investor Relations

Phone + 49 30 94 10 84 - 0

info@ezag.de

ISIN DE0005659700 WKN 565970